Aristotle Atlantic Partners LLC grew its position in shares of Merck & Co., Inc. (NYSE:MRK) by 14,083.9% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 695,010 shares of the company’s stock after buying an additional 690,110 shares during the quarter. Merck & Co., Inc. accounts for approximately 14.6% of Aristotle Atlantic Partners LLC’s investment portfolio, making the stock its biggest holding. Aristotle Atlantic Partners LLC’s holdings in Merck & Co., Inc. were worth $42,185,000 at the end of the most recent quarter.
Several other institutional investors have also recently bought and sold shares of MRK. Taylor Wealth Management Partners purchased a new position in Merck & Co., Inc. in the second quarter worth $110,000. Creative Financial Designs Inc. ADV grew its position in Merck & Co., Inc. by 155.2% in the second quarter. Creative Financial Designs Inc. ADV now owns 1,832 shares of the company’s stock worth $111,000 after acquiring an additional 1,114 shares in the last quarter. Clearwater Capital Advisors LLC purchased a new position in Merck & Co., Inc. in the first quarter worth $103,000. SRS Capital Advisors Inc. grew its position in Merck & Co., Inc. by 208.4% in the first quarter. SRS Capital Advisors Inc. now owns 1,983 shares of the company’s stock worth $108,000 after acquiring an additional 1,340 shares in the last quarter. Finally, Well Done LLC purchased a new position in Merck & Co., Inc. in the first quarter worth $115,000. 72.32% of the stock is currently owned by hedge funds and other institutional investors.
In related news, insider Roger M. Perlmutter sold 225,443 shares of the stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $75.27, for a total transaction of $16,969,094.61. Following the transaction, the insider now owns 366,998 shares in the company, valued at $27,623,939.46. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Julie L. Gerberding sold 36,218 shares of the stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $75.14, for a total transaction of $2,721,420.52. Following the transaction, the executive vice president now owns 82,481 shares in the company, valued at approximately $6,197,622.34. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,279,104 shares of company stock worth $92,845,846. Corporate insiders own 0.32% of the company’s stock.
MRK traded down $0.62 during midday trading on Friday, reaching $74.86. The company’s stock had a trading volume of 14,656,305 shares, compared to its average volume of 13,659,816. The stock has a market cap of $202.43 billion, a PE ratio of 18.81, a price-to-earnings-growth ratio of 2.04 and a beta of 0.73. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.04 and a current ratio of 1.44. Merck & Co., Inc. has a 1 year low of $52.83 and a 1 year high of $75.99.
Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Thursday, October 25th. The company reported $1.19 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.14 by $0.05. Merck & Co., Inc. had a net margin of 8.44% and a return on equity of 34.48%. The business had revenue of $10.79 billion for the quarter, compared to analysts’ expectations of $10.87 billion. Equities research analysts predict that Merck & Co., Inc. will post 4.34 EPS for the current year.
Merck & Co., Inc. declared that its Board of Directors has approved a share repurchase program on Thursday, October 25th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the company to repurchase up to 5.1% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s leadership believes its stock is undervalued.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, January 8th. Stockholders of record on Monday, December 17th will be issued a dividend of $0.55 per share. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.48. The ex-dividend date is Friday, December 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.94%. Merck & Co., Inc.’s dividend payout ratio is presently 48.24%.
COPYRIGHT VIOLATION WARNING: This piece was reported by BBNS and is owned by of BBNS. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://baseballnewssource.com/2018/11/10/aristotle-atlantic-partners-llc-has-42-19-million-holdings-in-merck-co-inc-mrk/2847099.html.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.
Featured Article: Diversification Important in Investing
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.